The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynairgen Share News (SNG)

Share Price Information for Synairgen (SNG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 6.20
Bid: 5.52
Ask: 7.00
Change: 0.08 (1.31%)
Spread: 1.48 (26.812%)
Open: 6.20
High: 6.20
Low: 6.20
Prev. Close: 6.12
SNG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Small caps round-up: LonZim, Lees Foods, blinkx ...

Wed, 27th May 2009 07:59

Zimbabwe-focused investment company LonZim said it is well-placed to benefit from any upturn in the southern African country's economy after investing in several sectors in the six months to February 28.The company posted a pre-tax loss of £911,000 as it invested in telecoms, aviation and hotel sectors."We are positive that the investment potential in Zimbabwe remains strong and that Zimbabwe has a very bright future as it looks to re-establish its presence as one of the major economies on the African continent," said chairman David Lenigas.Scottish cake and sweet supplier Lees Foods saw profits fall sharply in 2008 as it felt the impact of the collapse of the retail chain Woolworths and high raw material, power and distribution costs.Underlying pre-tax profits fell to £402,000 from £721,000 the previous year even as turnover climbed 8% to £16.1m."The fall in profits was primarily a result of a bad debt provision of £69,000 which was owed to the company by Woolworths and a significant increase in raw materials, power and distribution costs," Lees said.The board is recommending the dividend be maintained at 6.7p a share.Video search engine specialist blinkx has signed an agreement with US sport site FOXSports.com to add almost 1,000 video clips of sporting contests to its searchable video library. Globus Maritime saw gross revenues of $11.8m against $24m in the same period last year, while EBITDA was $7m against $18.8m.AIM-listed Africa-focused gas company Gasol has successfully raised £1m through a placing of shares with two of its principal shareholders, African Gas Development Corporation and Afren.Shares in Vyke Communications were marked lower Wednesday after the company said it issued 0.26m shares to settle supplier invoices totalling 1.75m Norwegian kroner. The newly issued shares represent 0.4% of Vyke's existing issued share capital.Smoker's cough treatment specialist Synairgen has raised £6.35m through a placing and subscription at 17p per share. The proceeds will finance two planned Phase IIa inhaled interferon beta studies in asthma and COPD.Bus maker Optare slipped into a loss £12m in 2008 reflecting costs of integrating two new businesses in difficult trading conditions. Turnover for the year was £49.2m (pro forma £82.4m) and loss from operations was £4.0m (pro forma £3.0m). Programme maker Shed Media has appointed Heather Rabbatts, Millwall FC's executive deputy chairman, as its new chairman. Coline McConville, who sat on the board of HBOS until early this year, and Marc Watson, from BT, are also joining as non-execs. Celebrity agent Formation Group saw profit before tax edge up to £1.83m in the six months ended 28 February from £1.76m a year ago on revenue from continuing operations of £18.8 versus £12.8m last time.The shares rallied yesterday after the group, whose clients include Simon Cowell and TV presenters Ant and Dec, confirmed it has received indications of interest from private equity group Gresham over 'certain parts' of the business. IFA Cavanagh's underlying profits fell to £779,000 (2007: £1.61m) on revenue of £17.5m (2007: £16.6m)in 2008. " Against a backdrop of what has probably been the most volatile period experienced in the financial markets since the 1930s, I consider this to be a satisfactory performance," chairman Paul Sinnet said.Powered glass specialist Romag posted an underlying loss of £1.3m in the half -year to March in what the company describes as the toughest conditions it has seen for 60 years. Unless conditions turned in the next few weeks it is unlikely it will be able to repeat the strong performance in sales and profits achieved in the second half of last year. Interim sales were 12% down at £10.2m, though a £2.7m currency hedging gain enabled it post a £1.1m profit.
More News
14 Mar 2019 14:47

Synairgen broadens SNG001 trial after committee review

(Sharecast News) - Respiratory drug discovery and development company Synairgen announced on Thursday that its data safety monitoring committee had completed its planned safety review of the second part of the phase 2 clinical trial of its inhaled interferon-beta (IFN-beta) therapeutic candidate, SNG001, in patients with chronic obstructive pulmonary disease (COPD).

Read more
14 Mar 2019 11:37

Synairgen Gets Positive Safety Review Of SNG001 Candidate

LONDON (Alliance News) - Synairgen PLC on Thursday said the Data Safety Monitoring Committee has completed its planned safety review of a clinical trial of therapeutic candidate, SNG001.The

Read more
25 Feb 2019 11:41

Synairgen Swings To Annual Loss As Costs Rise And Revenue Drops

LONDON (Alliance News) - Synairgen PLC on Monday said it swung to an annual loss due to higher research costs and the lack of a non-recurring GBP5 million payment from Pharmaxis received in 2018,

Read more
22 Oct 2018 11:53

Synairgen Begins Dosing For Next Stage Of SNG001 Clinical Trial

LONDON (Alliance News) - Synairgen PLC said Monday it has begun dosing for the next part of its SNG001 chronic obstructive pulmonary disease treatment trial.The respiratory drug discovery a

Read more
22 Oct 2018 09:20

Synairgen begins second part of SNG001 Phase II trial

(Sharecast News) - Respiratory drug discovery and development company Synairgen has started the second part of its Phase II clinical trial for its wholly-owned inhaled interferon-beta (IFN-beta) therapeutic candidate, SNG001, in patients with chronic obstructive pulmonary disease (COPD), it announced on Monday.

Read more
25 Sep 2018 13:48

Synairgen Fundraises To Progress Clinical Tests As Interim Loss Widens (ALLISS)

LONDON (Alliance News) - Synairgen PLC on Tuesday announced fundraising to cover the clinical trials of its wholly-owned antiviral therapy SNG001 after its loss widened in the first half of drug a

Read more
15 Mar 2018 12:57

Synairgen Swings To Profit On Lump Sum Payment As Pipeline Progresses

LONDON (Alliance News) - Respiratory drug development firm Synairgen PLC swung to a full year profit Thursday after a lump sum payment from a collaboration partner offset and

Read more
12 Oct 2016 09:52

Synairgen shares drop as AstraZeneca stops asthma drug study

(ShareCast News) - Synairgen's, the respiratory drug discovery and development company, hit the skids after its partner Astrazeneca announced that it has dropped its clinical trial for asthma drug AZD9412. AZD9412, which is a form of inhaled interferon beta, was investigated in an INEXAS trial in pa

Read more
22 Mar 2016 11:07

Synairgen Swings To Loss But Gets Good LOXL2 Trial Results

Read more
21 Mar 2016 16:06

Earnings, Trading Statements Calendar - Week Ahead

Read more
12 Nov 2015 11:35

DIRECTOR DEALINGS: Synairgen Directors Snap Up 163,000 Shares

Read more
16 Sep 2015 13:03

Synairgen's profit dips, R and D expenditure reduced

(ShareCast News) - Synairgen has posted an after tax loss of £0.91m for the six months to 30 June, down from a profit of £1.90m in the same period last year. The respiratory drug discovery and development company announced its unaudited interim results for the six months ended 30 June 2015. Researc

Read more
16 Sep 2015 09:50

Synairgen Swings To Loss As AstraZeneca Revenue Bump Doesn't Repeat

Read more
5 Aug 2015 10:21

Synairgen shares surge on research collaboration deal

(ShareCast News) - Synairgen surged after announcing that it has entered into a research collaboration deal with Australian pharmaceutical company Pharmaxis. The respiratory drug discovery and development company said they will develop a selective inhibitor to the lysyl oxidase type 2 enzyme to trea

Read more
5 Aug 2015 07:42

Synairgen Signs Research Collaboration Deal With Australia's Pharmaxis

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.